The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of radiation therapy on clonal hematopoiesis.
 
Leslie Ann Modlin
No Relationships to Disclose
 
N. Ari Wijetunga
No Relationships to Disclose
 
Minal Patel
No Relationships to Disclose
 
Teng Gao
No Relationships to Disclose
 
Ryan Ptashkin
No Relationships to Disclose
 
Michael R Sullivan
No Relationships to Disclose
 
Daniel W. Kelly
No Relationships to Disclose
 
Nicole Caltabellotta
No Relationships to Disclose
 
David B. Solit
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Illumina; Intezyne Technologies; Lilly; Loxo; Pfizer; QED Therapeutics; Vividion Therapeutics
Travel, Accommodations, Expenses - Merck KGaA
 
Michael F. Berger
Consulting or Advisory Role - Roche
Research Funding - Grail
 
Martin S. Tallman
Consulting or Advisory Role - Daiichi Sankyo; Delta-Fly Pharma; Jazz Pharmaceuticals; KAHR Medical; NOHLA Therapeutics; Oncolyze; Rigel; Tetraphase Pharma
Research Funding - Abbvie; ADC Therapeutics; Biosight; Cellerant; Orsenix
Patents, Royalties, Other Intellectual Property - UpToDate
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Jounce Therapeutics; Neophore; PapGene, Inc.; Personal Genome Diagnostics; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Caris Life Sciences; Cell Design Labs; Genocea Biosciences; Lyndra Therapeutics; Merck; Neophore; Personal Genome Diagnostics; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Travel, Accommodations, Expenses - Merck
 
Ahmet Zehir
Honoraria - Illumina
 
Elli Papaemmanuil
Stock and Other Ownership Interests - Tesaro (I)
Honoraria - Celgene; Novartis
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - My husband receives royalties for AZD5363 or AZD5393 (not sure) an AKT inhibitor through the institute of cancer research in th eUK (I)
Travel, Accommodations, Expenses - Celgene; Novartis; Tesaro (I)
 
Ross L. Levine
Leadership - Qiagen
Stock and Other Ownership Interests - C4 Therapeutics; Imago Pharma; IsoPlexis; Loxo; Qiagen
Honoraria - Amgen; Lilly
Consulting or Advisory Role - C4 Therapeutics; Celgene; Imago Pharma; IsoPlexis; Loxo; Prelude Therapeutics; Roche
Speakers' Bureau - Amgen; Lilly
Research Funding - Celgene; Prelude Therapeutics; Roche
Travel, Accommodations, Expenses - Auron Therapeutics; C4 Therapeutics; Constellation Pharmaceuticals; Genome; Incyte; Qiagen
 
Kelly L Bolton
Research Funding - GRAIL
 
Lior Zvi Braunstein
No Relationships to Disclose